Key Highlights

  • 9.03 percent was the gain in Tempus AI (NASDAQ:TEM) on October 5, 2026, according to published market data, while the pharmaceuticals and medical research sector slipped 0.15 percent, so the move was stock-specific.
  • No new Tempus release appeared on October 5, 2026; the latest ones were the October 1 ESMO abstracts, a September 28 FDA clearance for ECG-MR and a September 21 Recursion license extension.
  • USD 42 million of committed payments over three years replaced up to USD 84 million of discretionary fees in the extended Recursion data license, a reported term that lowers cost uncertainty for Tempus AI (NASDAQ:TEM).
  • 250,000 shares were sold by CEO Eric Lefkofsky on September 22, 2026 at USD 77.47, as reported, and insiders sold about 1.32 million shares over 90 days, a Supply overhang for TEM.

A Rebound Without a Fresh Release

Published market data show Tempus AI (NASDAQ:TEM) closed up 9.03 percent on October 5, 2026, extending a rebound from a mid-September low near USD 58.74, as reported. A second market data page put the day's close near USD 81.65, so the exact level conflicts and is not relied on here. The stock had fallen 6.1 percent to USD 76.87 on October 1, 2026. Company releases show an FDA clearance for the ECG-MR AI product on September 28, 2026, a Recursion data license extension to November 2029 on September 21, 2026, and 13 abstracts accepted for the European Society for Medical Oncology Congress 2026 on October 1, 2026. No Tempus announcement dated October 5, 2026 was found.

Momentum, Partnerships and the Personalis Deal

Tempus sells genomic testing and licenses de-identified clinical and molecular data to drug developers, and it uses AI tools such as FDA-cleared ECG software. The Recursion extension also gives it a nonexclusive license to Recursion's RNA foundation model. Separately, Tempus agreed on July 20, 2026 to buy Personalis in an all-stock deal reported at about USD 1.5 billion, with a collar tied to its own share price, so its stock level matters to the exchange ratio. Analyst views are split. UBS set a USD 70 target and Goldman Sachs USD 75 in neutral initiations, as reported, and the consensus target of about USD 71 sits below recent prices.

Risks and What to Watch

Tempus remains unprofitable, and the stock is volatile, with a reported Beta of about 3.7. Published intraday data on October 6, 2026 showed the shares near USD 78 after touching USD 87.99, so part of the jump has already reversed. Share issuance for Personalis brings dilution and integration risk, and insider selling continues. Watch the Personalis stockholder vote and S-4 amendments, the ESMO congress presentations, any further analyst target changes, the next quarterly report, and further sales disclosed in Form 4 filings. Peers in genomic testing and AI diagnostics also trade on funding and reimbursement news, so sector sentiment and Federal Reserve rate moves can amplify swings in a stock this volatile, regardless of company news.

Where Things Stand

Tempus AI (NASDAQ:TEM) jumped 9.03 percent on October 5, 2026 most likely on momentum after a run of positive company news, including the FDA ECG-MR clearance and the Recursion license, since no new announcement was found for that day. The rebound has partly faded in October 6 trading. Profitability, dilution from the Personalis deal and insider selling remain the main questions for the stock, and none is resolved yet.